Document Detail

What is the appropriate approach to prevention of thromboembolism in heart failure?
MedLine Citation:
PMID:  20024492     Owner:  NLM     Status:  MEDLINE    
Many studies suggest a higher incidence of thromboembolic syndromes such as stroke, peripheral arterial thrombosis and pulmonary embolism in patients with heart failure (HF), particularly those with left ventricular systolic dysfunction. As a result, some clinicians have chosen to treat patients with HF with anticoagulants as primary prevention against thromboembolic events. However, this practice is not well-supported by scientific data. Retrospective analyses of large HF trials have yielded contradictory results and randomised trials designed to specifically address this question have been under-populated and under-powered. As a result, there is no general consensus among professional societies in either recommending or advising against anticoagulants in HF. We hope that ongoing clinical trials, WARCEF in particular, will yield results that will guide clinicians in deciding for or against routine use of anticoagulants in HF.
Ronald S Freudenberger; Matthew M Schumaecker; Shunichi Homma
Publication Detail:
Type:  Journal Article; Review     Date:  2009-12-18
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  103     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-02     Completed Date:  2010-08-24     Revised Date:  2010-10-07    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  489-95     Citation Subset:  IM    
Center for Advanced Heart Failure Lehigh Valley Health Network Penn State College of Medicine Allentown, PA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / therapeutic use
Clinical Trials as Topic
Heart Failure / complications*
Premedication / methods
Thromboembolism / etiology,  prevention & control*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intra-patient variability of thromboelastographic parameters followingandadministration of recombina...
Next Document:  Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in...